• By Kevin E. Noonan

    Abbott Laboratories #1 The idea of a "golden age," almost always some time in the past, is a recurrent theme in history, literature, and myth. It is also the unspoken theme in Abbott's principal brief filed earlier this week in Therasense Inc. v. Becton Dickinson & Co., and that Golden Age has an exact date: right after the Federal Circuit rendered its en banc decision in Kingsdown Medical Consultants, Ltd. v. Hollister Inc., the last time the Court took up the question of inequitable conduct en banc.

    In an extensive (59 page) brief, Appellants argue that this case is not about whether the doctrine of inequitable conduct should be reformed, but whether it should be restored, specifically "to its origins in Supreme Court precedent; to the confines Congress intended in the 1952 Patent Act; to the standards this Court articulated en banc in Kingsdown Medical Consultants v. Hollister, Inc., 863 F.2d 867 (Fed. Cir. 1988); and to the standards that govern in other areas of law." This restoration is needed, the brief argues, because the Federal Circuit has "expanded" inequitable conduct "well beyond" the appropriate boundaries established by this earlier precedent and practice, and has resulted in an "'ongoing pandemic' of inequitable conduct charges," citing Judge Gajarsa's dissent in Taltech Ltd. v. Esquel Enterprises Ltd., 604 F.3d 1324, 1335 (Fed. Cir. 2010). Most provocatively, the brief charges that prevailing Federal Circuit precedent "has converted the federal courts into roving commissions to enforce standards of conduct before the PTO without regard to whether the alleged infractions had any impact." (And in an interesting strategic move, the brief cites extensively throughout to (now) Chief Judge Rader's many dissents and other pronouncements critical of the burgeoning expanse of conduct adjudged to be inequitable by the Court in recent years.)

    Supreme Court Building #2 The brief begins it argument by asserting that a court should render a patent unenforceable for inequitable conduct only when the patent has been obtained by fraud (or "conduct tantamount to fraud"). The brief cites the "holy trinity" of Supreme Court cases in this area — Keystone Driller Co. v. General Excavator Co., 290 U.S. 240 (1933); Hazel-Atlas Glass Co. v. Hartford-Empire Co., 322 U.S. 238, 250-51 (1944); Precision Instrument Mfg. Co. v. Automotive Maintenance Machinery Co., 324 U.S. 806 (1945) — to support its argument that the inequitable conduct doctrine (that a court should not enforce a patent in equity that was obtained due to inequitable conduct) was developed under fact circumstances that amounted to actual fraud (including perjury, subornation of perjury, bribery and other egregiously prosecution misconduct). The brief contrasts this with "missteps in making the legally and factually complex decisions applicants regularly make (such as whether to submit marginal prior art or potentially cumulative material)" as are commonly used today to support inequitable conduct charges (if not findings). The brief cites analogous trademark (citing In re Bose Corp., 580 F.3d 1240 (Fed. Cir. 2009)) and copyright (Eckes v. Card Prices Update, 736 F.2d 859, 861-62 (2d Cir. 1984)) standards that require similarly egregious misconduct to cancel a mark or strike a registration, which standards include the requirement that a challenger establish a "subjective intent to deceive, however difficult it may be to prove." Appellants argue that patent law should follow this example (particularly in view of the parallels the Supreme Court has drawn between patent and copyright based on the parallel recitation of these forms of protection in the Constitution, citing Sony Corp. of Am. v. Universal City Studios, Inc., 464 U.S. 417, 439 (1984) and eBay Inc. v. MercExchange L.L.C., 547 U.S. 388, 391-93 (2006)). Turning to the statute, the brief argues that the inequitable conduct defense was incorporated into the 1952 Patent Act (codified at 35 U.S.C. 282) "against the immediate backdrop" of Supreme Court precedent equating inequitable conduct with "fraudulent procurement" according to contemporary Supreme Court opinions (the "trinity").  Finally, the brief asserts that the equitable principles underlying the inequitable conduct doctrine are only equitably applied under circumstances when a patent is procured by actual fraud.

    Federal Circuit Seal Appellants next argue that the Federal Circuit's own precedent — Kingsdown Medical — requires "powerful proof of scienter" to support the "intent to deceive" prong of its inequitable conduct analysis:

    [T]he involved conduct, in light of all the evidence, including evidence indicative of good faith, must indicate sufficient culpability to require a finding of intent to deceive.  863 F.2d at 876 (emphasis added).

    The brief asserts that the intent requirement "cannot be inferred from materiality," and exhorts the Court to 'reinvigorate" the scienter requirement, that an applicant must be shown to have a "specific intent to deceive" the Office to support a finding of inequitable conduct (a standard not fulfilled by even "gross negligence"). Citing Star Scientific, Inc. v. R.J. Reynolds Tobacco Co., the brief sets out precisely what should be required (in Appellants' view) to establish an intent to deceive:

    The evidence must establish that, at the time, the applicant (1) knew of the information, (2) knew it was material to issuance of the patent, (3) made a deliberate decision to withhold or misrepresent it, and (4) intended to deceive the PTO.

    Deceptive intent must be "'the single most reasonable inference able to drawn from the evidence,'" Appellants argue, citing Orion IP, LLC, v. Hyundai Motor Am., 605 F.3d 967, 979 (Fed. Cir. 2010). This interpretation of the standard for establishing the intent to deceive requirement, Appellants argue, is consistent with both Supreme Court precedent and trademark and copyright law standards, as well as "sound policy considerations," not the least of which is to "restore the inequitable conduct doctrine to its proper bounds" and "stem a 'plague' of inequitable conduct charges" reminiscent of the situation that prevailed before the Federal Circuit rendered its Kingsdown decision. It is the Court's failure to stay true to (or even affirmatively disregard) the standards enunciated in Kingsdown that has resulted in the instant situation according to Appellants' brief. This section of the brief ends with an enumeration of the several, negative consequences of this falling away from the Kingsdown standard, both before the Patent Office (such as citing thousands of pages of documentary prior art) and in the courts.

    With regard to the materiality prong, the brief argues that "[i]n patent cases, 'materiality' is most properly interpreted to require proof that, 'if the Patent Office had been aware of the complete or true facts, the challenged claims would not have been allowed," citing the CAFC's predecessor court from Norton v. Curtiss, 433 F.2d 779, 794 (C.C.P.A. 1971). The brief argues in favor of a "but for" standard, wherein inequitable conduct should be found only where "the patent would not have issue[d] absent the misconduct." The brief says that Supreme Court precedent requires "but-for causation," citing Corona Cord Tire Co. v. Dovan Chemical Corp., 276 U.S. 358 (1928), where the Court reversed an inequitable conduct finding because the undisclosed information was "not the basis for [granting the patent] or essentially material to its issue."  But-for causation is also required under prevailing trademark and copyright law standards for analogous fraudulent procurement activity, the brief argues. When causation is unproven under this standard, the brief argues that courts (as opposed to the Office) should not render valuable patents unenforceable based on violations of PTO rules (as opposed to statutory requirements). And the brief argues that the court should not use Patent Office standards for assessing materiality, since these standards "serve a distinct purpose," being "necessarily . . . relatively broad" to serve their proper prophylactic function.

    The brief also exhorts the Court to "eliminate sliding scale" balancing, which reduces the extent of the proofs required to establish both the materiality and intent prongs of the prevailing standards for proving inequitable conduct. Using the "sliding scale" has permitted courts to use a stronger showing of materiality to "lower the burden for proving intent, and vice-versa," with the result that both the required standards (and burden for establishing) both materiality and intent to deceive are "diluted." Specifically, the brief calls out the "should have known" standard applied in some inequitable conduct cases as particularly problematic, since it substitutes a fraud standard for one that "sounds . . . in negligence" but carries a far higher, fraud-based penalty. Appellants ascribe the recurrent "plague" of inequitable conduct squarely to this diminution of the Kingsdown standards (citing Judge Newman's dissent in McKesson Info. Solutions, Inc. v. Bridge Med., Inc., 487 F.3d 897, 926 (Fed. Cir. 2007), in support). Interestingly, the brief does a little jurisprudential excavating on the origins of the sliding scale, and finds its genesis in American Hoist & Derrick Co. v. Sowa & Sons, Inc., which cited an earlier case, Digital Equipment Corp. v. Diamond, 653 F.2d 701, 716 (1st Cir. 1981), for the proposition:

    Questions of "materiality" and "culpability" are often interrelated and intertwined, so that a lesser showing of the materiality of the withheld information may suffice when an intentional scheme to defraud is established, whereas a greater showing of materiality of withheld information would necessarily create an inference that its nondisclosure was "wrongful."  725 F.2d at 1363.

    Ironically, this citation to the Digital Equipment case is the only support for this proposition in American Hoist & Derrick Co., and the brief notes that the only support for the assertion in Digital Equipment Corp. is a District of Massachusetts case, United States v. Standard Electric Time Co., 155 F. Supp. 949, 952-53 (D. Mass. 1957), that "contains no suggestion of an intent-materiality balancing test." As an illustration of how far off the rails the Federal Circuit has gone in misapplying the proper standard, the brief cites Ferring B.V. v. Barr Labs., Inc., 437 F.3d 1181 (Fed. Cir. 2006), which held that "intent to deceive may be inferred — indeed, inferred as a matter of law — where '(1) the applicant knew of the information; (2) the applicant knew or should have known of the materiality of the information; and (3) the applicant has not provided a credible explanation for the withholding.'" Such a standard "eviscerates Kingsdown" according to the brief, as it substitutes a mere negligence (not even a gross negligence) standard "that was expressly rejected in Kingsdown," citing Judge Linn's concurring opinion in Larson Mfg. Co. of S.D., Inc. v. Aluminart Prods. Ltd., 559 F.3d 1317 (Fed. Cir. 2009).

    Turning to the merits of the case at bar, the brief argues that the panel erred by substituting evidence of "high" materiality for a "diluted" intent standard. Specifically, the brief argues that the lawyer argument during U.S. prosecution was a reasonable interpretation of the argument made in a corresponding European application. Finally, the brief argues that the decision of the initial panel "abrogates the rule that lawyer argument is not material" evidence for (or against) patentability. In its analysis, the brief dissects the five reasons the District Court (and the initial CAFC panel) gave for supporting the determination of an intent to deceive, specifically arguing that at least one of the reasons — failure to give a credible explanation for non-disclosure — improperly "inverts the burden of proof" since the accused party "need not offer any explanation" unless the evidence establishes an intent to deceive clearly and convincingly.

    Absent any extensions, appellee Becton Dickinson & Co.'s brief is due August 25, and amicus curiae briefs must be filed no later than 7 days (i.e., August 2) after the principal brief of the party being supported is filed, or no later than 7 days after the Plaintiffs-Appellants' principal brief is filed when an amicus curiae does not support either party.

  •     By Sydney Kokjohn

    EOffice Action Last week, the U.S. Patent and Trademark Office celebrated the one-year anniversary of its e-Office Action (e-OA) program.  So far, the program has electronically notified patent applicants on more than 850,000 Office communications and reduced Patent Office paper usage by more than 9.2 million pages. 

    A pilot version of the program launched in December 2006 and later expanded to include additional USPTO offices (see "USPTO begins the 'e-Office Action' Pilot Program" and "e-Office Action Pilot Program Expansion").  In February of last year, the USPTO announced the pilot e-Office Action program would be made permanent in March.  There was initially some confusion about whether the program would be mandatory, but the Patent Office clarified that it was optional and that mailed communications would be sent if you were not enrolled (see "Optional e-Office Action Program to Begin in March").  The permanent program actually started on July 21, 2010 (see "USPTO e-Office Action Program Launches").

     

    Participation in the e-OA program is available to any registered patent attorney or agent or any pro se inventor, who is prosecuting an application associated with a customer number.  Applicants can opt-in or opt-out at any time.  This program allows applicants to receive notifications several days faster than when paper communications are mailed.  Those who opt-in to the program receive daily email notifications (including on the weekends) that Office communications are available for download through private PAIR.  The email notifications replace the postal mailing of Office communications for these applicants.  Applicants can enroll in the e-OA program through private PAIR by selecting the option to "Receive Correspondence Notification via e-Mail" on the Customer Details for Customer Number screen.  Other beneficial features of the program include:

    • Notifications sent to up to three emails addresses; and
    • Reminder postcards when a new e-Office Action has not been viewed within seven days and requires a reply.

    Some of the top document codes for e-Office Actions include non-final rejections, notices of allowance, and filing receipts (a spreadsheet of top document codes can be found here).  Participants in the e-OA program are invited to share their experiences by emailing PAIR@USPTO.gov.  Additional information about the e-OA program can be found here.

  •     By Ignacio Sanchez Echagüe —

    INPI The Argentine Patent Office (Instituto Nacional de la Propiedad Industrial, INPI) has issued Regulation No. 147/2010, which restricts the ability of applicants to file divisional applications once substantive examination has begun.

    The regulation, which went into effect on July 16, 2010, allows applicants to file divisional applications until notice of substantive examination has been served.  No divisional applications will be allowed thereafter, unless they are made in response to a request from the Argentine Patent Office.  Once substantive examination has begun, if the examiner finds that the application has more than one object, the applicant will be requested to divide it within 30 days; should the applicant fail to do so, the application will be deemed as having been abandoned.  In all cases, the basic application must be alive and pending.

    This new regulation modifies the prior practice of the Argentine Patent Office, which allowed applicants to file divisional applications at any time during prosecution up to the final decision of the main application.

    Regulation No. 147/2010 raises concerns as it may unlawfully restrict patent rights, thus providing grounds for challenge.

    Ignacio Sanchez Echagüe [IMSE@marval.com.ar] is an attorney with Marval, O'Farrell & Mairal in Buenos Aires, Argentina.

  •     By Juan Serrano —

    Mexico Seal The Mexican General Health Law was reformed on June 11, 2009 to include an article 222 bis, which defined biotechnological drugs, and allowed for the approval of "biocomparables."  The decree came into force on September 8, 2009, and the Ministry of Health had a 180-day period to issue all specific regulations pertaining to the approval of these biocomparables.

    Even though the 180-day period expired on March 8, 2010, work on the project of regulations has continued, with input being provided by both the Mexican Association of Pharmaceutical Research (AMIIF) and the National Association of Drug Manufacturers (ANAFAM).

    COFEPRIS This past week, COFEPRIS (the Mexican regulatory authority) made the project of regulations available to the public, through the official website of the Federal Commission for Regulatory Improvement (COFEMER).

    At this point, a period of 30 working days has been given to any interested party that wishes to provide comments to this project through COFEMER's website, after which the project can be either published or further analyzed.

    The main items in this project are:

    • A definition of comparability tests between an innovator and a biocomparable drug.

    • An indication that biocomparable drugs will use the same name for the active ingredient as the innovator.

    • The Health law regulations currently contain a 3-year period Roche-Bolar-like research exemption (related to the possibility of submitting an application for a marketing authorization before patent expiration, with intent to launch after the date of expiry).  This 3-year period is eliminated, and the submission can now be made at any time.  The modification in the corresponding article will also be applicable to chemical drugs.

    • The timelines that COFEPRIS will have for approval of both innovator and biocomparable drugs are established.

    A copy of this document can be found here.

    Juan Serrano is an attorney with Olivares & Cia in Mexico City and frequent contributor to Patent Docs.  He can be contacted at jls@olivares.com.mx.

  •     By
    Donald Zuhn


    USPTO Seal

    Last
    week, the U.S. Patent and Trademark Office published a notice in the Federal
    Register (75 Fed. Reg. 42079)
    to clarify how the Office will treat certain letters submitted by
    applicants and patentees regarding the Office's patent term adjustment (PTA) determinations.  In particular, the notice addresses
    situations in which an applicant or patentee submits a letter (other than requests for reconsideration under 37 C.F.R. § 1.705) stating that the
    Office's PTA determination is greater than what the applicant or patentee
    believes is appropriate.  In such
    situations, the notice states that the Office will no longer review the letter
    or issue a certificate of correction, but instead will place the letter in the
    application file without further review.

    When reconsideration of a PTA
    determination is desired, the notice reminds applicants and patentees that the procedures
    set forth in 37 C.F.R. § 1.705 for requesting reconsideration must be used.  Alternatively,
    a patentee may file a terminal disclaimer disclaiming any period considered in
    excess of the appropriate PTA.  The
    notice states, however, that "the USPTO does not require an applicant or
    patentee to file either a request for reconsideration under 37 CFR 1.705 or a
    terminal disclaimer when the patent term adjustment indicated on a notice of
    allowance, issue notification, or patent is greater than what the applicant or
    patentee believes is appropriate."

    The Office notes that a 2004 revision to the M.P.E.P. permitted
    applicants and patentees to wait until a patent issues and then request a
    certificate of correction if a notice of allowance or patent specified a PTA
    that was longer than expected (M.P.E.P. § 2733).  Despite this revision to the M.P.E.P., however, the notice declares
    that "the USPTO has long maintained that a request for a certificate of
    correction under either 35 U.S.C. 254 or 255 is not an appropriate venue for
    seeking a change to the patent term adjustment indicated on a patent,"
    because "[i]t would render the provisions of 35 U.S.C. 154(b)(3)
    superfluous if patent term adjustment determinations could be revised at any
    time during the life of the patent via a certificate of correction under 35
    U.S.C. 254 or 255."

    The
    notice does offer two circumstances in which it would be appropriate to issue a
    certificate of correction to revise a PTA determination:  to make the PTA determination consistent with (1) the PTA determined in a decision on a request for
    reconsideration under 37 C.F.R. § 1.705, or (2) "the total patent term adjustment indicated on the Patent
    Application Information Retrieval (PAIR) screen that displays the patent term
    adjustment calculation for the patent."  According to the notice, the Office will issue
    certificate of corrections to revise a PTA determination only under the two
    circumstances described above.  As
    a result:

    If
    the applicant or patentee wants the USPTO to reconsider its patent term
    adjustment determination, the applicant or patentee must use the procedures set
    forth in 37 CFR 1.705 for requesting reconsideration of a patent term
    adjustment determination, whether the USPTO's patent term adjustment
    determination is greater than or less than the adjustment that the applicant or
    patentee believes to be appropriate.

    The Office notes that the M.P.E.P. will be revised to correct the improper guidance provided in the 2004 revision.

  •     By Sherri
    Oslick

    Gavel_2About
    Court
    Report:  Each week we will report briefly on recently filed
    biotech and pharma cases.


    Roche Palo Alto LLC et al. v. Lupin Pharmaceuticals, Inc. et al.
    1:10-cv-01988; filed July 20, 2010 in the District
    Court of Maryland

    • Plaintiffs:  Roche Palo Alto LLC; Gilead Palo
    Alto, Inc.; Gilead Sciences, Inc.
    • Defendants:  Lupin Pharmaceuticals, Inc.; Lupin
    Ltd.

    Roche Palo Alto LLC et al. v. Lupin Pharmaceuticals, Inc. et al.
    2:10-cv-03561; filed July 14, 2010 in the District
    Court of New Jersey

    • Plaintiffs:  Roche Palo Alto LLC; Gilead Palo
    Alto, Inc.; Gilead Sciences, Inc.
    • Defendants:  Lupin Pharmaceuticals, Inc.; Lupin
    Ltd.

    The
    complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos.
    6,303,607 ("Method for Administering a Sustained Release Ranolazine
    Formulation," issued October 16, 2001), 6,479,496 ("Methods for Treating
    Angina with Ranolazine," issued November 12, 2002), 6,503,911 ("Sustained
    Release Ranolazine Formulations," issued January 7, 2003), 6,525,057 (same
    title, issued February 25, 2003), 6,562,826 (same title, issued May 13, 2003),
    6,617,328 (same title, issued September 9, 2003), 6,620,814 (same title, issued
    September 16, 2003), 6,852,724 (same title, issued February 8, 2005), and
    6,864,258 (same title, issued March 8, 2005), all licensed to Gilead, following
    a Paragraph IV certification as part of Lupin's filing of an ANDA to
    manufacture a generic version of Gilead's Ranexa® (ranolazine, used to treat
    chronic angina).  View the New
    Jersey complaint
    here.


    Bayer Schering Pharma AG et al. v. Teva Pharmaceuticals USA Inc.
    et al.

    1:10-cv-00616; filed July 20, 2010 in the District
    Court of Delaware

    • Plaintiffs:  Bayer Schering Pharma AG; Bayer
    HealthCare Pharmaceuticals Inc.; Schering Corp.
    • Defendants:  Teva Pharmaceuticals USA Inc.; Teva
    Pharmaceuticals Industries Ltd.

    Infringement of U.S. Patent No. 7,696,206 ("2-phenyl
    Substituted Imidazotriazinones as Phosphodiesterase Inhibitors," issued April
    13, 2010) following a Paragraph IV certification as part of Teva's filing of an
    ANDA to manufacture a generic version of plaintiffs' Levitra® (vardenafil hydrochloride,
    used to treat erectile dysfunction).  View the complaint
    here.


    Promote Innovation LLC v. K-V Pharmaceutical Co. et al.
    2:10-cv-00254; filed July 20, 2010 in the Eastern
    District of Texas

    • Plaintiff:  Promote Innovation LLC
    • Defendants:  K-V Pharmaceutical Co.; Ther-Rx
    Corp.

    False marking based on defendants' marking of their
    Gynazole-1® products indicating that these products are covered by U.S. Patent
    Nos. 4,078,071 ("Derivatives of substituted N-alkyl imidazoles,"
    issued March 7, 1978), 4,551,148 ("Vaginal delivery systems and their
    methods of preparation and use," issued November 5, 1985), and 4,636,202 ("Medicament
    applicator with plunger assembly and automatically-openable closure therefore,"
    issued January 13, 1987), which are expired.  View the complaint
    here.


    Promote Innovation LLC v. Schering Corp. et al.
    2:10-cv-00248; filed July 19, 2010 in the Eastern
    District of Texas

    • Plaintiff:  Promote Innovation LLC
    • Defendants:  Schering Corp.; Merck &
    Co., Inc.; Cima Labs Inc.

    False marking based on defendants' marking of their
    Clarinex® products indicating that these products are covered by U.S. Patent
    Nos. 4,659,716 ("Antihistaminic 8-(halo)-substituted
    6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines,"
    issued April 21, 1987) and 4,863,931 ("Antihistaminic fluoro substituted
    benzocycloheptapyridines," issued September 5, 1989), which are
    expired.  View the complaint
    here.


    Promote Innovation LLC v. Roche Diagnostics Corp. et al.
    2:10-cv-00249; filed July 19, 2010 in the Eastern
    District of Texas

    • Plaintiff:  Promote Innovation LLC
    • Defendants:  Roche Diagnostics Corp.; Roche
    Diagnostics Operations, Inc.

    False marking based on defendants' marking of their
    Accu-Chek® products indicating that these products are covered by U.S. Patent
    Nos. RE36,268 ("Method and apparatus for amperometric diagnostic analysis,"
    issued August 17, 1999), 4,999,582 ("Biosensor electrode excitation
    circuit," issued March 12, 1991), 4,924,879 ("Blood lancet device,"
    issued May 15, 1990), and 5,053,199 ("Electronically readable information
    carrier," issued October 1, 1991), which are either unenforceable or
    expired.  View the complaint
    here.


    Promote Innovation LLC v. Gloucester Pharmaceuticals, Inc. et
    al
    .
    2:10-cv-00241; filed July 16, 2010 in the Eastern
    District of Texas

    • Plaintiff:  Promote Innovation LLC
    • Defendants:  Gloucester Pharmaceuticals, Inc.;
    Celgene Corp.

    False marking based on defendants' marking of their
    Istodax® products indicating that these products are covered by U.S. Patent No.
    4,977,138 ("FR901228 substance and preparation thereof," issued
    December 11, 1990), which is expired.  View the complaint
    here.


    Promote Innovation LLC v. Pfizer Inc. et al.
    2:10-cv-00242; filed July 16, 2010 in the Eastern
    District of Texas

    • Plaintiff:  Promote Innovation LLC
    • Defendants:  Pfizer Inc.; Pharmacia & Upjohn
    Co., Inc.; Bayer Healthcare Pharmaceuticals Inc.

    False marking based on defendants' marking of their
    Glyset® products indicating that these products are covered by U.S. Patent No. 4,639,436
    ("Antidiabetic 3,4,5-trihydroxypiperidines," issued January 27, 1987),
    which is expired.  View the
    complaint
    here.


    Promote Innovation LLC v. Abbott Laboratories Inc. et al
    .
    2:10-cv-00246; filed July 16, 2010 in the Eastern
    District of Texas

    • Plaintiff:  Promote Innovation LLC
    • Defendants:  Abbott Laboratories Inc.; Takeda
    Pharmaceutical Co. Ltd.

    False marking based on defendants' marking of their
    Lupron® products indicating that these products are covered by U.S. Patent Nos.
    4,652,441 ("Prolonged release microcapsule and its production,"
    issued March 24, 1987), 4,677,191 ("Copolymer and method for producing the
    same," issued June 20. 1987), 4,728,721 ("Polymer, production and use
    thereof," issued March 1, 1988), 4,849,228 (same title, issued July 18,
    1989), 4,917,893 ("Prolonged release microcapsules," issued April 17,
    1990), 4,005,063 ("[Des-gly].sup.10 -GnRH nonapeptide anide analogs in
    position 6 having ovulation-inducing activity," issued January 25, 1977),
    and 4,005,194 ("Treatment of prostatic hyperplasia," issued January
    25, 1977) which are expired.  View
    the complaint
    here.


    Bayer Schering Pharma AG et al v. Lupin Ltd. et al.
    1:10-cv-01914; filed July 15, 2010 in the District
    Court of Maryland

    • Plaintiffs:  Bayer Schering Pharma AG; Bayer
    Healthcare Pharmaceuticals Inc.
    • Defendants:  Lupin Ltd.; Lupin Pharmaceuticals,
    Inc.

    Infringement of U.S. Patent Nos. RE37,564 ("Composition
    for Contraception," issued February 26, 2002), RE37,838 (same title,
    issued September 10, 2002), RE38,253 (same title, issued September 16, 2003),
    and 5,569,652 ("Dihydrospirorenone as an antiandrogen," issued
    October 29, 1996) following a Paragraph IV certification as part of Lupin's
    filing of ANDAs to manufacture a generic version of Bayer's Yaz® (drospirenone and
    ethinyl estradiol, used for oral contraception) and Bayer's Yasmin®
    (drospirenone and ethinyl estradiol, used for oral contraception).  View the complaint
    here.


    Bayer Schering Pharma AG et al v. Lupin Ltd et al.
    2:10-cv-01166; filed July 15, 2010 in the District
    Court of Nevada

    • Plaintiffs:  Bayer Schering Pharma AG; Bayer
    Healthcare Pharmaceuticals Inc.
    • Defendants:  Lupin Ltd.; Lupin Pharmaceuticals,
    Inc.

    Infringement of U.S. Patent Nos. RE37,564 ("Composition
    for Contraception," issued February 26, 2002), RE37,838 (same title,
    issued September 10, 2002), and RE38,253 (same title, issued September 16,
    2003) following a Paragraph IV certification as part of Lupin's filing of an
    ANDA to manufacture a generic version of Bayer's Yaz® (drospirenone and ethinyl
    estradiol, used for oral contraception).  View the complaint
    here.


    Bayer Schering Pharma AG et al. v. Lupin Ltd. et al.
    1:10-cv-05423; filed July 15, 2010 in the Southern
    District of New York

    • Plaintiffs:  Bayer Schering Pharma AG; Bayer
    Healthcare Pharmaceuticals Inc.
    • Defendants:  Lupin Ltd.; Lupin Pharmaceuticals,
    Inc.

    Infringement of U.S. Patent No. 5,569,652 ("Dihydrospirorenone
    as an antiandrogen," issued October 29, 1996) following a Paragraph IV
    certification as part of Lupin's filing of an ANDA to manufacture a generic
    version of Bayer's Yasmin® (drospirenone and ethinyl estradiol, used for oral
    contraception).  View the complaint
    here.


    King
    Pharmaceuticals, Inc. et al. v. Sandoz, Inc.

    3:10-cv-03568; filed July 14, 2010 in the District
    Court of New Jersey

    • Plaintiffs:  King Pharmaceuticals, Inc.; Meridian
    Medical Technologies, Inc.
    • Defendant:  Sandoz, Inc.

    Infringement
    of U.S. Patent No. 7,449,012 ("Automatic Injector," issued November
    11, 2008) following a Paragraph IV certification as part of Sandoz's filing of
    an ANDA to manufacture a generic version of Meridian's EpiPen® Auto-Injector
    (epinephrine, used to treat anaphylaxis).  View the complaint
    here.


    Genzyme Corp. v. Lupin Ltd. et al.
    1:10-cv-01906; filed July 14, 2010 in the District
    Court of Maryland

    • Plaintiff:  Genzyme Corp.
    • Defendants: Lupin Ltd.; Lupin Pharmaceuticals,
    Inc.

    Genzyme Corp. v. Watson Laboratories, Inc.
    1:10-cv-01863; filed July 9, 2010 in the District
    Court of Maryland

    The complaints in these cases are substantially
    identical.  Infringement of U.S.
    Patent No. 5,667,775 ("Phosphate-Binding Polymers for Oral Administration,"
    issued on September 16, 1997) following a Paragraph IV certification as part of
    defendants' filing of an ANDA to manufacture a generic version of Genzyme's
    Renvela® (sevelamer carbonate, used for the control of serum phosphorus in
    patients with chronic kidney disease on dialysis).  View the Watson Laboratories complaint
    here.


    Stiefel Laboratories Inc. et al. v. Perrigo Israel
    Pharmaceuticals Ltd. et al
    .
    1:10-cv-00592; filed July 12, 2010 in the District
    Court of Delaware

    • Plaintiffs:  Stiefel Laboratories Inc.; Stiefel
    Research Australia Pty Ltd.
    • Defendants:  Perrigo Israel Pharmaceuticals Ltd.;
    Perrigo Co.

    Infringement of U.S. Patent Nos. 6,730,288 ("Mousse
    Composition," issued May 4, 2004) and 7,029,659 (same title, issued April
    18, 2006) following a paragraph IV certification as part of Perrigo's filing of
    an ANDA to manufacture a generic version of Stiefel's OLUX-E® (clobetasol
    propionate foam 0.05%, used to treat moderate to severe scalp dermatoses).  View the complaint
    here.


    Siemens Healthcare Diagnostics Inc. v. Enzo Life Sciences, Inc.
    4:10-cv-40124; filed July 9, 2010 in the District
    Court of Massachusetts

    Review of the decision of the Board of Patent
    Appeals and Interferences awarding priority of invention to Enzo in the
    interference between U.S. Patent Application No. 08/479,995 ("Assay Method
    Utilizing Polynucleotide Sequences," filed June 7, 1995), assigned to Enzo
    and U.S. Patent No. 5,124,246 ("Nucleic Acid Multimers and Amplified
    Nucleic Acid Hybridization Assays Using Same," issued June 23, 1992),
    assigned to Siemens.  View the
    complaint
    here.


    Elan Pharma International Ltd. et al v. Teva Pharmaceuticals USA,
    Inc.

    2:10-cv-03495; filed July 9, 2010 in the District
    Court of New Jersey

    • Plaintiffs:  Elan Pharma International Ltd.;
    Fournier Laboratories Ireland Ltd.
    • Defendant:  Teva Pharmaceuticals USA, Inc.

    Infringement of U.S. Patent Nos. 5,145,684 ("Surface
    Modified Drug Nanoparticles," issued September 8, 1992), 7,276,249 ("Nanoparticulate
    Fibrate Formulations," issued October 2, 2007), and 7,320,802 ("Methods
    of Treatment Using Nanoparticulate Fenofibrate Compositions," issued
    January 22, 2008), all licensed to Abbott, following a Paragraph IV
    certification as part of Teva's filing of an ANDA to manufacture a generic
    version of Abbott's Tricor® (fenofibrate, used in the treatment of increased
    triglyceride levels).  View the
    complaint
    here.


    Abbott Laboratories et al. v. Teva Pharmaceuticals USA, Inc.
    2:10-cv-03482; filed July 9, 2010 in the District
    Court of New Jersey

    • Plaintiffs:  Abbott Laboratories; Laboratories
    Fournier S.A.
    • Defendant:  Teva Pharmaceuticals USA, Inc.

    Infringement of U.S. Patent Nos. 6,277,405 ("Fenofibrate
    Pharmaceutical Composition Having High Bioavailability and Method for Preparing
    It," issued August 21, 2001), 7,037,529 (same title, issued May 2, 2006),
    and 7,041,319 ("Fenofibrate Pharmaceutical Composition Having High
    Bioavailabilty," issued May 9, 2006) following a Paragraph IV
    certification as part of Teva's filing of an ANDA to manufacture a generic
    version of Abbott's Tricor® (fenofibrate, used in the treatment of increased
    triglyceride levels).  View the
    complaint
    here.


    Pfizer, Inc. et al. v. Apotex Inc. et al.
    1:10-cv-05272; filed July 9, 2010 in the Southern
    District of New York

    • Plaintiffs:  Pfizer, Inc.; Pfizer Ireland
    Pharmaceuticals
    • Defendants:  Apotex Inc.; Apotex Corp.

    Infringement of U.S. Patent No. 6,110,940 ("Salts
    of an Anti-Migraine Indole Derivative," issued August 29, 2000) following
    a Paragraph IV certification as part of Apotex's filing of an ANDA to
    manufacture a generic version of Pfizer's Relpax® (eletriptan hydrobromide,
    used for the acute treatment of migraine with our without aura).  View the complaint
    here.


    AstraZeneca Pharmaceuticals LP et al. v. Torrent Pharmaceuticals
    Ltd. et al
    .
    1:10-cv-00584; filed July 8, 2010 in the District
    Court of Delaware

    • Plaintiffs:  AstraZeneca Pharmaceuticals LP; IPR
    Pharmaceuticals Inc.; AstraZeneca AB; Brigham and Women's Hospital Inc.
    • Defendants:  Torrent Pharmaceuticals Ltd.; Torrent
    Pharma Inc.

    Infringement of U.S. Patent Nos. 6,858,618 ("Use
    of Rosuvastatin (ZD-4522) in the Treatment of Heterozygous Familial
    Hypercholesterolemia," issued February 22, 2005) and 7,030,152 ("Systematic
    Inflammatory Markers as Diagnostic Tools in the Prevention of Atherosclerotic
    Diseases and as Tools to Aid in the Selection of Agents to be Used for the
    Prevention and Treatment of Atherosclerotic Disease," issued April 18,
    2006) certification as part of Torrent's filing of an amended ANDA to
    manufacture a generic version of AstraZeneca's Crestor® (rosuvastatin calcium,
    used to treat high cholesterol).  View the complaint
    here.






  • Calendar

    July 26-27, 2010 – Advanced
    Patent
    Prosecution Workshop 2010: Claim Drafting & Amendment Writing
    (
    Practising
    Law
    Institute) –
    New
    York, NY

    July
    29-31, 2010 –
    Intensive
    Patent Law
    Training Workshop
    (Chisum
    Patent Academy) –
    Seattle,
    WA

    August
    5-10, 2010 – 2010
    ABA Annual Meeting
    (American
    Bar
    Association) –
    San
    Francisco, CA

    August
    11, 2010 –
    "Bilski:
    Implications of the Supreme Court's
    Long-Awaited Ruling:  Strategies
    for Prosecuting or Challenging Patent Process Claims Going Forward
    " (
    Strafford)
    1:00
    – 2:30 PM (EDT)

    August
    16-17, 2010
    Advanced
    Patent
    Prosecution Workshop 2010: Claim Drafting & Amendment Writing
    (
    Practising
    Law
    Institute) –
    San
    Francisco,
    CA

    August
    18-19, 2010 (Postponed to January 26-27, 2011) –
    The
    Life Sciences
    Lawyer's Guide to Patent Term Adjustment and Patent Term Extensions
    ***
    (American
    Conference
    Institute) –
    New
    York, NY

    August
    25-26, 2010 –
    FDA
    Boot Camp
    ***

    (American
    Conference
    Institute) –
    San
    Francisco, CA

    September
    1-2, 2010 –
    7th
    Annual Pharmaceutical Law Summer School
    (
    IBC
    Legal) –
    London, UK

    September
    7-9, 2010 –
    BioPatent
    Design
    (
    Pharma
    IQ) –
    Munich,
    Germany

    September
    12-14, 2010 –
    2010
    Annual Meeting
    (
    Intellectual
    Property Owners Association) –
    Atlanta,
    GA

    September
    15, 2010
    Prior
    Art &
    Obviousness 2010: Current Trends
    in Sections 102 & 103
    (
    Practising
    Law
    Institute) –
    San
    Francisco, CA

    September
    16, 2010 –
    Developments
    in
    Pharmaceutical and Biotech Patent Law 2010
    (
    Practising
    Law
    Institute) –
    New
    York,
    NY (
    Groupcasts to be held in
    Philadelphia, PA; Pittsburgh,
    PA;
    Mechanicsburg, PA; New Brunswick, NJ; and Boston, MA)

    September
    20-22, 2010 –
    2nd
    Annual Business of
    Biosimilars
    (
    Institute for
    International Research) –
    Boston,
    MA

    September
    22-23, 2010 –
    Biosimilars
    & Biobetters: Aligning
    Business & Science for Success
    *** (
    SMi
    Conferences) –
    London, UK

    September
    27-28, 2010 –
    FDA
    Boot Camp
    *** (
    American
    Conference
    Institute) –
    Boston,
    MA

    October
    6-7, 2010 –
    Maximizing
    Pharmaceutical Patent
    Lifecycles
    *** (
    American
    Conference
    Institute) –
    New
    York, NY.

    ***Patent Docs is a media partner of this conference or CLE


  • New York #1 American Conference
    Institute (ACI) will be holding its 11th Maximizing Pharmaceutical Patent
    Lifecycles conference on October 6-7, 2010 in New York, NY.  The conference will allow attendees to:

    • Understand how
    the introduction of biosimilars has profoundly altered pharmaceutical patent
    life cycle strategies;
    • Appreciate the
    relationship between life cycle management, brand optimization and new product
    development;
    • See how the
    Federal Circuit is paving the way for Patent Reform;
    • Determine when
    and how secondary patents — for both small and large molecules should be
    pursued;
    • Comprehend how
    the clear delineation between written description and enablement is influencing
    claims drafting strategies for drugs and biologics via Ariad v. Lilly;
    • Assess how the
    Court's determination in Bilski
    regarding methods claims may affect areas such as personalized medicine and
    other new pharmacological technologies;
    • Examine the
    impact of Caraco on skinny labeling,
    carve-outs and Orange Book listing determinations;
    • Identify
    circumstances under which exclusivity is forfeited; and
    • Navigate the
    boundaries of the safe harbor.


    MPPL_Brochure In particular,
    ACI's faculty will offer presentations on the following topics:

    The remaking of the patent
    endgame;
    • Patent reform revisited:  Pondering its impact on the
    pharmaceutical industry;
    • Understanding the particulars,
    peculiarities and politics of biosimilars and their impact on pharmaceutical
    patent life cycle management;
    • Of biosimilar applications (BPCIA) and
    ANDAs (Hatch-Waxman);
    • New patent term adjustment and patent
    term extension decisions and their significance for small and large molecules;
    • Obviousness continued:  How KSR
    and its progeny are impacting the patent life of drug and biological products;
    Ariad
    v. Lilly
    :  The reaffirmation of
    written description and enablement and their collective role in patent life
    cycle management — presented in part by Orange Book Blog author Aaron
    Barkoff;
    Biliski,
    Prometheus and Myriad:  Understanding
    the madness over methods claims in the pharmaceutical industry;
    • Eye on the CAFC and district
    courts:  Life cycle lessons derived
    from Paragraph IV litigation;

    FTC keynote:  Competition considerations for
    pharmaceutical patent life cycle management — presented by Markus H. Meier,
    Assistant Director of the Health Care Division for the Bureau of Competition of
    the Federal Trade Commission;

    New controversies and
    concerns associated with Orange Book listing and labeling strategies;
    • Exclusivity:  Modes, methods, forfeitures and relinquishments;

    FDA keynote:  Update on FDA activities relative to
    pharmaceutical patent life cycles for small and large molecules — Elizabeth
    Dickinson, Associate Chief Counsel for the Office of the Chief Counsel of the
    U.S. Food and Drug Administration; and


    Learning to navigate the new limits and boundaries of the safe harbor.

    Two pre-conference
    workshops will be offered on October 5, 2010.  The first, entitled "Hatch-Waxman and BPCIA 101 — A Primer
    on IP Basics and Regulatory Fundamentals" will offer presentations on the
    following topics:

    • Understanding
    pre-commercialization concerns relative to small molecules and biologics;
    • The nature of the
    approval process for drugs and biologics: 
    What every pharmaceutical patent attorney should know; and
    • Patent and IP
    overview for drugs and biologics: 
    Hatch-Waxman, trade dress, and more.

    A second
    pre-conference workshop on "Pharmaceutical Patent Life Cycle Strategies
    for the EU and Emerging Markets" will also be offered on October 5, 2010.

    A post-conference
    workshop, entitled "The Master Class on Patent Term Adjustment and Patent
    Term Extensions for Pharmaceutical and Biological Patents," will be held
    on October 8, 2010.  This post-conference
    workshop will provide practical advice as well as tips and techniques for PTA
    and PTE, take attendees through the intricacies of the four major ways of
    getting more time on their patents, and provide the tools that attendees need
    to accomplish this goal.

    The agenda for the
    Maximizing Pharmaceutical Patent Lifecycles conference can be found here.  A complete brochure for this
    conference, including an agenda, detailed descriptions of conference sessions,
    list of speakers, and registration form can be obtained here.


    ACI - American Conference Institute The registration
    fees are $2,295 (conference only), $2,895 (conference plus one workshop),
    $3,295 (conference plus two workshops), or $3,495 (conference plus all three
    workshops).  Those registering by
    September 9, 2010 will receive a $200 discount (for all but the conference plus
    three workshops), and those registering on or before August 6, 2010 will
    receive a $300 workshop (for all but the conference plus three workshops).  Those interested in registering for the
    conference can do so here,
    by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.

    Patent Docs is a media partner of ACI's Maximizing Pharmaceutical Patent
    Lifecycles conference.


  • Boston Skyline American Conference
    Institute (ACI) will be holding the next session of its FDA Boot Camp
    conference on September 27-28, 2010 in Boston, MA.  ACI faculty will help attendees:

    • Master the
    complexities of pharmaceutical iP and the regulatory balance between brand name
    and generic products;
    • Analyze the
    future of follow-on biologics following recent health care reform legislation;
    • Recognize the
    pivotal role of labeling in the drug and biologics approval process;
    • Comprehend the
    structure of the FDA and the roles of the three major agency centers:  CDER, CBER, and CDHR;
    • Understand the
    basics of the approval processes for drugs, biologics and devices, including
    in-depth discussion of the application, pre-approval and post-approval requirements;
    • Evaluate when
    preemption arguments may offer protection for life sciences companies;
    • Assess what
    marketing activities may constitute off-label promotion;
    • Navigate the
    protocols of adverse events reporting; and
    • Develop a
    practical working knowledge of clinical trials for drugs and biologics and the
    clearance process for devices.


    FBC_brochure In particular,
    ACI's faculty will offer presentations on the following topics:

    • The basics:  Understanding and working with the FDA
    — Jurisdiction, functions, organization, and operations;
    • The nature of the
    approval process;
    • Understanding the
    clinical trial process for drugs and biologics;
    • Patent and IP
    overview for drugs and biologics: 
    Hatch-Waxman, trade dress, and more;
    • Spotlight on
    follow-on (comparable or biosimilar) biologics and the 2010 health care reform
    legislation;
    • Drugs and
    biologics:  Labeling;
    • Preemption
    fundamentals;
    • Marketing and
    promotion;
    • Non-patent
    exclusivity (part of the conference's patent track);

    Bioequivalence:  What patent lawyers
    need to know (patent track);
    • Adverse events monitoring,
    pharmacovigilance and risk management; and
    • Medical device
    essentials:  Premarket and
    post-market requirements.

    The agenda for the
    Maximizing Pharmaceutical Patent Lifecycles conference can be found here.  A complete brochure for this
    conference, including an agenda, detailed descriptions of conference sessions, list
    of speakers, and registration form can be obtained here.


    ACI - American Conference Institute The registration
    fee for this conference is $2,195. 
    Those registering by August 27, 2010 will receive a $200 discount.  Those interested in registering for the
    conference can do so here,
    by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.

    Patent Docs is a media partner of ACI's FDA Boot Camp conference.

  •     By
    James DeGiulio —

    Teva
    and Novartis Settle Patent Dispute over Zometa

    Teva
    Pharmaceuticals Industries Ltd. and Novartis Corp. have reached an agreement to
    settle their patent suit over a generic version of Zometa, a drug used to prevent
    skeletal fractures.


    Teva #2 Teva
    first sent Novartis two Paragraph IV notices on June 10, 2008, claiming that
    Novartis' U.S. Patent No. 4,939,130 was either invalid, unenforceable, or wouldn't be
    infringed by Teva's proposed generic.  Novartis claimed that Teva had inappropriately sent the Paragraph IV
    notices before filing its ANDA (see "Court Report," August 3, 2008).  Thus, Novartis asked the District Court to declare Teva's
    Paragraph IV notices invalid and require the company to file new notices before
    the clock on the 30-month stay can start.


    Novartis The
    parties subsequently reached an agreement, with Judge Sue Robinson of the
    U.S. District Court for the District of Delaware signing off on the parties'
    stipulation of dismissal.  The stipulation dismisses without prejudice all
    claims, counterclaims, and defenses in the action.  Both Teva and Novartis will pay their own costs and
    attorneys' fees.  No other details were available.

    View
    Novartis' complaint
    here.

    Judge
    Robinson's dismissal order can be found
    here.


    Teva,
    Sun Fail to Overturn Jury Verdict Finding Pfizer Protonix Patent Valid


    Sun Pharma Teva
    and Sun's allegations that Pfizer's Protonix patent was invalid as obvious and
    invalid for double patenting were rejected in a recent court decision, which upholds
    an earlier jury verdict affirming the validity of Pfizer's U.S. Patent No. 4,758,579,
    covering the heartburn drug.


    Pfizer Wyeth,
    the licensee of the '579 patent and now part of Pfizer, and Altana Pharma AG,
    now part of Nycomed, brought a patent infringement suit against Teva in May
    2004 following Teva's ANDA filing.  In September 2007,
    Judge
    Jose
    L. Linares of the U.S. District Court for the District of New Jersey
    found that Teva had raised sufficient
    issues over the patent's validity, and denied a motion for preliminary
    injunction to stop Teva from launching generic versions of Protonix.  In April,
    a jury found the '579 patent valid, disagreeing with allegations by Teva and
    other generic firms that the patent was invalid based on obviousness and
    double-patenting (see "Biotech/Pharma Docket," May 10, 2010).

    Judge
    Linares has now affirmed the April 23 jury verdict, finding that all issues regarding validity
    and infringement of the Protonix patent have been decided in Pfizer's favor.  Pfizer will now pursue its damage claims from the at-risk launch of generic
    versions of the drug by Teva and Sun.  Teva reiterated its belief the patent was
    invalid and unenforceable and planned to pursue all available legal remedies,
    including appeals.


    Sandoz
    Loses Motion for Interlocutory Appeal in Effexor Patent Suit with Wyeth


    Sandoz Sandoz's
    bid for an interlocutory appeal has been denied following a grant of partial summary
    judgment for Wyeth in a patent infringement suit over the depression and anxiety
    drug Effexor.


    Wyeth Wyeth
    sued Sandoz in 2007, claiming that Sandoz's ANDA infringed three patents, U.S. Patent Nos. 6,419,958, 6,403,120, and 6,274,171 (see "Court Report," July 1, 2007).  Following a Markman hearing,
    Wyeth moved for summary judgment regarding Sandoz's direct infringement,
    active inducement of infringement, and contributory infringement of several
    claims in the three patents.
      On March 12,
    Judge James Denver of the U.S. District Court for the Eastern District of North
    Carolina granted Wyeth's motion for summary judgment over all the infringement
    claims against Sandoz.  At the same
    time, he denied Sandoz's motion for summary judgment for noninfringement and
    invalidity, finding the defendant's arguments based on inappropriate claim
    construction.  Following this ruling, Sandoz asked Judge Denver to immediately
    certify his order granting summary judgment to Wyeth for an interlocutory
    appeal.

    On
    July 14, Judge James ruled that Sandoz failed to meet the standard necessary
    for an interlocutory appeal.  Judge
    Denver had construed the term "extended release formulation" broadly
    to include a formulation that releases the active ingredient at a slower rate
    than the original formulation.  Judge Denver found no substantial ground for
    difference of opinion over the term such that an interlocutory appeal was
    warranted.  The judge also ruled
    that because the issues raised by Sandoz were not controlling questions of law,
    an interlocutory appeal would not materially advance the litigation.

    Judge
    James' order can be found
    here.

    James
    DeGiulio has a doctorate in molecular biology and genetics from
    Northwestern University and
    is a graduate of Northwestern
    University
    School of Law.  Dr. DeGiulio is a member of MBHB's 2010 associate class
    and he can be
    contacted at degiulio@mbhb.com.